Screener
Immix Biopharma, Inc. IMMX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liability - current | 125,392 | 139,339 |
| Total current liabilities | 10,539,658 | 10,110,546 |
| Operating lease liability – long term | 912,343 | 933,625 |
| Total liabilities | 11,452,001 | 11,044,171 |
| Commitments and contingencies | - | - |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | - | |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 53,084,455 shares issued and 53,012,092 shares outstanding at March 31, 2026 and 53,023,466 shares issued and 52,951,103 shares outstanding at December 31, 2025 | 5,307 | 5,301 |
Document
FAQ
- What is Immix Biopharma, Inc.'s total liabilities?
- Immix Biopharma, Inc. (IMMX) reported total liabilities of $11.45M in Q1 2026.
- How has Immix Biopharma, Inc.'s total liabilities changed year-over-year?
- Immix Biopharma, Inc.'s total liabilities increased by 11.2% year-over-year, from $10.3M to $11.45M.
- What is the long-term trend for Immix Biopharma, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s total liabilities has grown at a 80.6% compound annual growth rate (CAGR), from $575K to $11.04M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Immix Biopharma, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude